Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
Conditions
Interventions
Intervention1: Triple Metronomic: TAB. Erlotinib 150mg OD
Capsule. Celecoxib 200mg BD
TAB. Methorexate 9mg/m2 weekly
Control Intervention1: Physician Choice Therapy: INJ. methotrexate or
INJ. Docetaxe
Sponsors
NO
Eligibility
Inclusion criteria
Inclusion criteria: 1.Head and neck cancers planned for palliative chemotherapy, post first line palliative chemotherapy failure a.Patients who have failed within 6 months of curative treatment, where chemotherapy was a part will be considered. 2.Age : Any age >=18 years 3.ECOG performance status 4.Histopathologically or FNAC (Fine needle aspiration cytology) proof of cancer. 5.Participants must have normal organ and marrow function as defined below: a.Leukocytes >=3,000/mcL b.Platelets >=100,000/mcL c.Total bilirubin d.AST(SGOT)/ALT(SGPT) e.Calculated Creatinine clearance > 30 ml/min 6.The effects of chemotherapy on the developing human fetus are teratogenic. Hence women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of protocol. 7.Both men and women of all races and ethnic groups are eligible for this trial. 8.Willing and able to comply with all study requirements. 9.Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
Exclusion criteria: 1.Participants who are currently receiving any other investigational agents. 2.Patients with QTc prolongation defined as QTc interval greater than 480 ms in view of risk of sudden cardiac death associated with use of ondansetron. Patients in whom an initial evaluation QTc is prolonged but with medical interventions it is restored to normal are eligible for the study. 3.History of allergic reactions attributed to compounds of similar chemical or biologic composition to any agents used in study. 4.Uncontrolled intercurrent illness including, but not limited to, active tuberculosis, uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, renal failure (on dialysis), active gastrointestinal bleeding, cerebrovascular accidents within last 1 year, inflammatory bowel disease, known hyperkalemia ( CTCAE version 5 grade 3 or above which is persistent over 1 week) or psychiatric illness/social situations that would limit compliance with study requirements. Patients who have uncontrolled hypertension or diabetes or other chronic medical condition at initial evaluation but in whom these conditions are controlled with medical intervention can be assessed for eligibility. 5.Pregnant women and breastfeeding women are excluded from this study because Chemotherapy agents have the potential for teratogenicity or abortifacient effects. 6.Patients who are able to receive immunotherapy (both financially and medically fit for the same), will be excluded from this study All inclusion and exclusion criteria have to be satisfied for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survivalTimepoint: 6 Months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.QOL 2.Adverse event 3.Progression free survivalTimepoint: 1.At baseline one month two month and at six months post treatment completion 2. During the study treatment 3. From the date of randomization to date of progression | — |
Countries
India
Contacts
Public ContactBhavesh P Bandekar
MPMMCC HBCH Varanasi
Outcome results
None listed